A six month combination study of Esbriet (pirfenidone) and nintedanib in patients with Idiopathic pulmonary fibrosis (IPF)

Trial Profile

A six month combination study of Esbriet (pirfenidone) and nintedanib in patients with Idiopathic pulmonary fibrosis (IPF)

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Sep 2017

At a glance

  • Drugs Nintedanib (Primary) ; Pirfenidone (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 19 Sep 2017 New trial record
    • 12 Sep 2017 Data were presented at the European Respiratory Society (ERS) congress, as reported in a Roche Media Release.
    • 12 Sep 2017 Results published in the Roche Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top